MRD Archives - Geneseeq Technology Inc. | A Precision Oncology Company

May 16, 2023

Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer

March 9, 2023

Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer

January 24, 2023

Geneseeq receives CE Marks for MRD and MCED tests.

October 12, 2022

Interesting findings on ctDNA-based MRD detection in patients with resectable non-small cell lung cancer by Geneseeq

August 31, 2021

Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer

May 18, 2021

Geneseeq study shows ctDNA evaluation in early postoperative phase predicts risk of recurrence in colorectal cancer